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We have been examining the issue of healthcare workers’ exposure to antineoplastic drugs for nearly a
decade and have observed that there appears to be more publications on the subject matter originating
from Europe than from North America. The concern is that ﬁndings from Europe may not be general-
izable to North America because of differences in handling practices, regulatory requirements, and
training. Our objective was to perform a literature review to conﬁrm our observation and, in turn,
identify gaps in knowledge that warrants addressing in North America. Using select keywords, we
searched for publications in PubMed and Web of Science. All papers were initially classiﬁed according to
the originating continent and then categorized into one or more subject categories (analytical methods,
biological monitoring, occupational exposure, surface contamination, and probability of risk/exposure).
Our review identiﬁed 16 papers originating from North America and 55 papers from Europe with surface
contamination being the subject matter most often studied overall. Based on our results, we are of the
opinion that North American researchers need to further conduct dermal and/or urinary drug contam-
ination studies as well as assess the exposure risk faced by healthcare workers who handle antineoplastic
drugs. Trends in exposure levels should also be explored.
 2014, Occupational Safety and Health Research Institute. Published by Elsevier. All rights reserved.1. Introduction
A number of health risks associated with healthcare workers’
exposure to antineoplastic drugs have been established since the
1970s [1]. Occupational exposure to these agents have led to a
range of health outcomes reported in healthcare workers including
acute effects [2], cardiotoxicity [3], reproductive toxic effects [4e6],
and chromosomal damageda precursor to cancer development
[7,8]. Nearly 40 years after the association between healthcare
workers and the adverse effects of antineoplastic drug exposure
was established, the matter remains a concern today for a number
of reasons. First, the incident rate of cancer is steadily increasing
and, in turn, the use of antineoplastic drugs is growing [9]. Second,
existing safe drug handling practices may not effectively eliminate
the risk potential as drug contamination of surfaces is prevalent inPublic Health, Ryerson University
erms of the Creative Commons At
ribution, and reproduction in any
l Safety and Health Research Institmultiple departments within a hospital [10,11]. Lastly, the number
and variety of healthcare workers potentially exposed to antineo-
plastic drugs has increased because the use of these agents for
treating nonmalignant diseases has expanded [1]. Compounding
the problem is the fact that occupational exposure limits have not
been established for these drugs by any of the recognized agencies
that produce such exposure thresholds (e.g., American Conference
of Governmental Industrial Hygienists threshold limit values,
German maximum workplace concentration).
Our group of researchers at the University of British Columbia in
Vancouver, Canada, have been examining the issue of healthcare
workers’ exposure to antineoplastic drugs for more than a decade.
During our review of the literature for background and research
purposes, we noticed a peculiar ﬁnding that a larger proportion of
the publications on this subject matter originate in continental, 350 Victoria Street, POD 247C, Toronto, Ontario, Canada M5B 2K3.
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
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Although the information from Europe is of value, the ﬁndings and
conclusions may not necessarily be transferable to North American
healthcare facilities due to differences in standards of practice,
legislative requirements and education/training protocols between
the two continents. Although results from Europe may not neces-
sarily be generalizable to North America, they are of value by
initiating meaningful discussions and acting as an impetus for
similar research projects to be conducted in North American fa-
cilities. (We know that there are publications based in other con-
tinents such as Asia and Australia that have examined the issue of
healthcare workers’ exposure to antineoplastic drugs. However, we
have observed that the work focuses primarily on cross-sectional
evaluations of current exposure conditions and do not elucidate
contributing factors related to the risk of exposure. We are conﬁ-
dent that future work from these other continents will offer valu-
able insight into this subject matter).
The purpose of this paper was to test our observation that more
publications regarding healthcare workers’ exposure to antineo-
plastic drugs originate from Europe than in North America. We
conducted a review of the published literature for articles that
addressed this topic, categorized them according to subject matter,
and then tallied the ﬁndings to determine where knowledge gaps
exist, if any, between the two continents. From the potential
knowledge gaps identiﬁed, our goal was to identify and prioritize
additional research that is worthy of consideration in North
American facilities to better our understanding of healthcare
workers’ exposure to antineoplastic drugs and the underlying risk
that these exposures may present.
2. Materials and methods
We sought articles from two common literature databases:
PubMed andWeb of Science. Select keywords were used to identify
articles for the purposes of this review. The keywords were anti-
neoplastic drugs (along with its synonyms antineoplastic agents
and cytotoxic drugs), healthcare, occupational exposure, analytical
methods, biological monitoring, risk assessment, surface contami-
nation, and exposure monitoring. The keywords were systemati-
cally combined together in order to conduct the literature search.
For example, “antineoplastic drugs” AND “occupational exposure”
AND “healthcare” was one combination. There were a total of 18
combinations of keywords and all combinations were applied to
each of the two databases.
We aimed to identify original research articles (i.e., nonreview)
using the aforementioned keywords with the following exclusion
criteria: (1) not written in English; (2) not published between
January 1, 2004 and December 31, 2012. The year 2004 was chosen
as this was the release date of the original NIOSH (National Institute
for Occupational Safety and Health) Alert regarding antineoplastic
and other hazardous drugs [1]; (3) research conducted outside of
North America or continental Europe (as deﬁned by worldatlast.-
com [12]); (4) nonhuman studies; and (5) not full reports (i.e.,
letters to the editor).
Every full-text article that met the inclusion criteria was initially
classiﬁed according to the continent of origin of the study (North
America or Europe). Next, the paper was reviewed and categorized
into one or more of the following ﬁve categories based on its
subject matter: analytical methods (e.g., development and valida-
tion of a novel laboratory analytical method), biological monitoring
(e.g., blood or urine samples), occupational exposure, surface
contamination, and probability of risk/exposure. For the purposes
of this paper, “occupational exposure” was deﬁned as those
instances where dermal and/or airborne contamination levels were
measured. “Probability of risk/exposure” was deﬁned asdeterminants of exposure and/or studies in which comparisons
between exposed and nonexposed populations were made. The
number of articles was tallied according to the ﬁve subject cate-
gories, stratiﬁed by the continent, using the COUNTIF function in
Microsoft Excel (Microsoft, Redman, WA, USA).
3. Results
Our search of the two literature databases resulted in a total of
80 publications that matched our inclusion criteria. Of these, nine
were removed because they were deemed irrelevant (i.e., confer-
ence proceedings, not concerning occupational health, or not
related to healthcare settings). Therefore, 71 papers remained in
the studyd16 from North America and 55 that originated in con-
tinental Europe.
When these 71 papers were categorized according to their
subject matter, the topics discussed in order of frequency (from
highest to lowest) were surface contamination, probability of risk/
exposure, biological monitoring, occupational exposure, and
analytical methods. For each of the ﬁve topics, there were always
more instances of European-based publications than North
American, with a minimum 3-fold difference (Table 1).
4. Discussion
Our analysis suggests that European scientists have been more
active in researching the area of healthcare workers’ exposure to
antineoplastic drugs than their North American counterparts. From
2004 until 2012, there were three times as many papers from
Europe compared to North America. We therefore believe that
there are opportunities in North America to further our under-
standing of this occupational health issue.
Surface contamination was the topic most commonly examined
in the literature. As Connor et al [10] recently indicated, every paper
that has examined surface contamination has found at least one
instance of drug residual present. Therefore, we suggest that there
is likely no need to explore this particular topic any further. How-
ever, as no occupational exposure limits have been established, we
recommend that North American researchers and/or occupational
hygienists consider developing suitable hygienic guidance values
based on surface contamination levels that have been recently
obtained from Canadian and American healthcare facilities. Such
hygienic guidance values have previously been proposed in two
European countriesdone for Germany [63] and another set of
values for Sweden [39]. Given the potential difference in practices
and training regimens, the hygienic guidance values developed in
Europemay not be practical or suitable to North American facilities.
European researchers have provided leadership in the area of
developing methods for quantifying antineoplastic drug contami-
nation in various matrixes. Researchers in North America can
simply adopt and reﬁne these analytical methods according to local
needs without the need for rigorous validation. However, it would
be ideal if a research facility in North America were capable of
performing some of these reported analyses because there may be
sample stability concerns if these samples were to be shipped
overseas. Upon review of the papers that have developed analytical
methods, there appears to be a need to ﬁnd biological markers of
exposure that are speciﬁc to the different types of antineoplastic
drugs [83] as well as address the issues associated with the large
interindividual variability of volume output when collecting urine
samples [37].
Inhalation, dermal, urine, and blood samples have been
collected by various researchers in order to understand healthcare
workers’ exposure to antineoplastic drugs. Our results suggest that
European researchers have examined occupational exposures
Table 1
Summary of literature review ﬁndings with tally of articles based on continent of origin and topics addressed













Acampora et al 2005 [13]   
Barbieri et al 2006 [14]  
Brouwers et al 2007 [15]   
Bussieres et al 2007 [16]  
Caciari et al 2012 [17]   
Castiglia et al 2008 [18]  
Cavallo et al 2005 [19]    
Cavallo et al 2009 [20]   
Chappuy et al 2012 [21]   
Chu et al 2012 [22]  
Connor et al 2005 [23]   
Connor et al 2010 [10]     
Constantinidis et al 2011 [24]   
Crauste-Manciet et al 2005 [25]   
Fabrizi et al 2012 [26]   
Favier et al 2012 [27]  
Forges et al 2011 [28]  
Fransman et al 2004 [29]   
Fransman et al 2005 [30]    
Fransman et al 2006 [31]   
Fransman et al 2007 [32]   
Fransman et al 2007 [33]     
Harrison et al 2006 [34]   
Hedmer et al 2004 [35]    
Hedmer et al 2005 [36]  
Hedmer et al 2008 [37]  
Hedmer et al 2008 [38]   
Hedmer and Wohlfart 2012 [39]  
Hon et al 2011 [40]  
Hon et al 2011 [41]   
Konate et al 2011 [42]     
Kopp et al 2012 [43]    x
Kopp et al 2012 [44]   x
Lalande et al 2012 [45]   x
Mader et al 2009 [46]   
Mason et al 2005 [47]    
Massoomi et al 2008 [48]   
McDiarmid and Condon 2005 [49]  
Ndaw et al 2010 [50]   
Nussbaumer et al 2010 [51]   
Nussbaumer et al 2012 [52]   
Nygren et al 2005 [53]   
Nygren et al 2008 [54]
Odraska et al 2011 [55]   
Odraska et al 2012 [56]   
Pieri et al 2010 [57]   
Pretty et al 2012 [58]     
Roberts et al 2006 [59]   
Rubino et al 2006 [60]    
Sabatini et al 2005 [61]   
Sabatini et al 2012 [62]    
Schierl et al 2009 [63]   
Schierl et al 2010 [64]  
Schierl et al 2012 [65]   
Schulz et al 2005 [66]  
Sessink et al 2011 [67]  
Sottani et al 2004 [68]   
Sottani et al 2005 [69]   
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Sottani et al 2007 [70]   
Sottani et al 2008 [71]   
Sottani et al 2010 [72]   
Sottani et al 2012 [73]    
Stover and Achutan 2011 [74]   
Testa et al 2007 [7]   
Touzin et al 2009 [75]  
Touzin et al 2010 [76]   
Tuerk et al 2011 [77]   
Turci et al 2011 [78]    
Turk et al 2004 [79]  
Ursini et al 2006 [80]    
Villarini et al 2011 [81]   
Zock et al 2011 [82]  
North American subtotals 16 5 2 1 13 7
European subtotals 55 16 23 16 37 23
Overall totals 71 21 25 17 50 30
Saf Health Work 2014;5:169e174172levels more often than North Americans (Table 1). This may be
because some researchers consider the collection of surface
contamination samples to be sufﬁcient markers of exposure and
therefore personal samples do not need to be collected [63]. This is
understandable given that surface wipes are more convenient to
collect and are not invasive, and one can obtain a larger sample size
with less stringent ethical considerations compared with samples
taken from individuals. However, this may mask the true extent of
exposure as we have recently reported that, although surface
contamination is widespread within a healthcare facility, surface
contamination levels are not necessarily indicative of the exposure
risks faced by healthcare workers [11,84]. As such, it is recom-
mended that surface contamination be used to identify those job
categories at risk of exposure but that personal samples, such as
dermal wipes or biological samples, be collected from healthcare
workers to evaluate their actual level of risk [84]. Not only have our
European colleagues conducted more studies on occupational
exposure than we have, but they have also looked at trends in
exposure levels over time [33,46,72]. This is an important consid-
eration as analysis of trends is a means to evaluate the effectiveness
of control measures in reducing the risk of exposure, and we
recommend that North American researchers consider initiating
this type of study.
Table 1 indicates that 30 papers determined the probability of
risk/exposure due to occupational exposure to antineoplastic
drugsdmore than two-thirds of which (n ¼ 23) originated from
Europe. One of the means to conﬁrm that workers are at risk of
exposure to antineoplastic drugs and their associated health effects
is to perform studies comparing workers that are exposed versus
those that are not exposed. Our review found seven such stud-
iesdsix from European researchers [7,17,19,20,60,81] and only one
originating in North America [10]. Because there are likely differ-
ences in handling practices and training regimens, the ﬁndings
reported in Europe may not be representative of the conditions in
North American facilities. We, therefore, suggest that more North
American researchers adopt a mandate to assess the level of risk
associated with the antineoplastic drug exposure levels faced by
their healthcare workers by conducting exposed versus nonex-
posed studies.
Limitations regarding this project need to be mentioned. We
treated all antineoplastic drugs alike; however, these drugs differ intheir physical and chemical properties that affect their pharmaco-
kinetics as well as their toxicity. This review had a limited scope
whereby publications from other continents and gray literature,
including dissertations, were not considered. Some of the studies
resulted in multiple related publications; however, they were
treated as independent papers in our review. When we combined
these related publications, the ratio of European to North American
publications remained greater than 3:1 and did not change our
conclusions (not shown). In addition, the number of search terms
used was somewhat limited. We did attempt to use other terms
such as “healthcare facilities” and “anticancer drugs”, but this
either resulted in no hits or duplicate results.
In conclusion, our review of the literature indicates that since
2004, more publications regarding healthcare workers’ exposure to
antineoplastic arise from Europe than in North America. We believe
there are a number of research initiatives that can be undertaken in
North America to better understand this subject matter. This in-
cludes occupational exposure studies (i.e., personal samples
quantifying antineoplastic drug contamination levels in healthcare
workers) and the subsequent assessment of the risk associated
with these exposure levels. In addition, an analysis of the trends in
exposure levels from North American facilities is also suggested.
Given the known health effects of antineoplastic drugs, we need to
better understand the occupational exposures to antineoplastic
drugs in North American workplaces and, where necessary,
implement control measures to protect our healthcare workers to
reduce the level of risk.
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